European drug regulator rejects Alzheimer's treatment Leqembi from Biogen, Eisai
July 26, 2024 at 08:42 AM EDT
The committee said Leqembi's effect on delaying cognitive decline does not outweigh "the risk of serious side effects associated with the medicine."
